OptimizeRx Announces Pricing of Public Offering of Common Stock
2021年2月9日 - 11:10PM
OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading
provider of digital health solutions for life science companies,
physicians and patients, today announced the pricing of the
previously announced underwritten public offering of 1,325,000
shares of its common stock at a price to the public of $49.50 per
share. The gross proceeds to OptimizeRx from the offering, before
deducting the underwriting discounts and commissions and estimated
offering expenses payable by OptimizeRx, are expected to be
approximately $65.6 million. OptimizeRx granted the underwriters a
30-day option to purchase up to an additional 198,750 shares of
common stock at the public offering price, less underwriting
discounts and commissions. The offering is expected to close on or
about February 11, 2021, subject to customary closing conditions.
The net proceeds of the offering will be used for
general corporate purposes, which may include future acquisitions.
OptimizeRx does not have any immediate arrangements, commitments or
understandings regarding any future acquisitions.
William Blair & Company, L.L.C. and RBC Capital
Markets, LLC are acting as joint book-running managers for the
offering. Roth Capital Partners and Lake Street Capital Markets,
LLC are acting as financial advisors for the offering.
An automatic shelf registration statement on Form
S-3 (File No. 333-252844) relating to the shares was filed with the
Securities and Exchange Commission (the “SEC”) on February 8, 2021
and is effective. The offering is being made only by means of a
prospectus supplement and the accompanying prospectus. Before you
invest, you should read the prospectus in the registration
statement, the preliminary prospectus supplement, and other
documents OptimizeRx has filed with the SEC for more
complete information about OptimizeRx and the offering. Copies of
the registration statement, the preliminary prospectus supplement
and accompanying prospectus may be obtained on the SEC’s website at
http://www.sec.gov or from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606; Phone: (800) 621-0687; Email:
prospectus@williamblair.com or RBC Capital Markets, LLC, Attn:
Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY
10281-8098, by telephone at (877) 822-4089 or by email at
equityprospectus@rbccm.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About OptimizeRx
OptimizeRx is a digital health company that
provides communications solutions for life science companies,
physicians and patients. Connecting over half of healthcare
providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health
platform helps patients afford and stay on medications. The
platform unlocks new patient and physician touchpoints for life
science companies along the patient journey, from point-of-care, to
retail pharmacy, through mobile patient engagement.
Important Cautions Regarding
Forward-Looking Statements
Certain information contained in this press release
includes “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995, including
statements related to the gross proceeds we expect to receive from
the offering, the expected use of the net proceeds from the
offering and the expected date of the closing of the offering. We
may, in some cases use terms such as “expects,” “plans,” “will” or
other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current expectations that
involve risks, potential changes in circumstances, assumptions and
uncertainties. Any or all of the forward-looking statements may
turn out to be wrong, or be affected by inaccurate assumptions we
might make or by known or unknown risks and uncertainties as a
result of various important factors, including the uncertainties
related to market conditions and the completion of the public
offering on the anticipated terms, or at all. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to our business in general,
please refer to our preliminary prospectus supplement filed with
the Securities and Exchange Commission (SEC) on February 8, 2021
under the heading “Risk Factors” and those documents incorporated
by reference therein, which includes our Annual Report on Form 10-K
filed with the SEC on March 26, 2020. You are cautioned not to
place undue reliance on these forward-looking statements, which are
made only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
OptimizeRx ContactDoug Baker,
CFOTel (248) 651-6568 x807dbaker@optimizerx.com
Media Relations Contact Maira
Alejandra, Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations ContactRon
Both, CMATel (949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024